Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Reider, S; Novacek, G; Haas, T; Gröchenig, HP; Platzer, R; Koch, R; Kump, PK; Reinisch, W; Moschen, A.
Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel DiseaseWorking Group of the Austrian Society of Gastroenterology and Hepatology (OGGH)
Z GASTROENTEROL. 2023;
Doi: 10.1055/a-2150-2156
Web of Science
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Constantini-Kump Patrizia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The humanized monoclonal anti-a4 ss 7-integrin- antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedolizumab. This work supplements a position paper on the value of vedolizumab as a first-line biologic that has already been published and offers useful recommendations for clinical practice.
- Find related publications in this database (Keywords)
- Chronisch entzundliche Darmerkrankung
- Colitis ulcerosa
- Morbus Crohn
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Crohn's Disease